nct_id: NCT06330064
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-03-26'
study_start_date: '2024-04-10'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Ifinatamab deruxtecan'
long_title: A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And
  Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic
  Solid Tumors (IDeate-PanTumor02)
last_updated: '2025-09-30'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Daiichi Sankyo
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 520
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Participants must meet all of the following criteria to be included in the study:'
- Common Inclusion Criteria for All Participants
- 1. Participant must have at least 1 lesion, not previously irradiated, amenable
  to core biopsy and must consent to provide a pretreatment biopsy tissue sample.
  An archival tumor tissue sample obtained within 6 months of consent and after progression
  during/after treatment with the participant's most recent cancer therapy regimen
  is also acceptable.
- "2. Participants ages \u226518 years (follow local regulatory requirements if the\
  \ legal age of consent for study participation is \\>18 years)."
- 3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance
  imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version
  1.1 (RECIST v1.1), as assessed by the investigator.
- 4. Documentation of radiological disease progression on or after the previous standard-of-care
  regimen in the advanced/metastatic setting.
- 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Additional Inclusion Criteria for EC Participants
- 1. Pathologically or cytologically documented EC of any histological carcinoma subtype
  or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch
  repair status.
- 2. Relapse or progression after a platinum-containing systemic treatment and an
  immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Subjects
  with actionable target tumor mutation should have been previously treated with targeted
  therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or
  carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the
  subject progressed within 6 months after completion of therapy.
- Additional Inclusion Criteria for HNSCC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic squamous
  cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding
  nasopharynx, nasal cavity and paranasal sinuses, and unknown primary.
- 2. Has disease progression after platinum-based and ICI treatment, whether administered
  in combination or separately. Subjects with actionable target tumor mutation should
  have been previously treated with targeted therapy, with a maximum of 2 prior therapy
  lines for unresectable or metastatic HNSCC.
- 3. Participants without radiographic evidence of major blood vessel invasion/infiltration
  or tumor demonstrating a \>90-degree abutment or encasement of a major blood vessel.
- "4. Participants with no prior history of Grade \u22653 bleeding as per the National\
  \ Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0\
  \ within 28 days prior to the start of study drug related to the current head and\
  \ neck cancer may be included in the study."
- 5. Documented p16 status for oropharyngeal cancer (historical results are acceptable
  if available).
- Additional Inclusion Criterion for PDAC Participants
- 1\. Pathologically or cytologically documented unresectable or metastatic pancreatic
  adenocarcinoma that has relapsed or progressed after 1 prior line of gemcitabine-based
  systemic therapy in the locally advanced/metastatic setting or after 2 lines of
  therapy if the subject has actionable target tumor mutation and has been previously
  treated with targeted therapy. No prior treatment with topoisomerase I inhibitors,
  such as irinotecan or topotecan.
- Additional Inclusion Criteria for CRC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic CRC with
  microsatellite stable status.
- 2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine
  plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF)
  monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy,
  as clinically indicated, or relapse or progression after 2 lines of therapy if the
  subject has received targeted therapy.
- 'Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as
  1 line of prior systemic therapy if there is documented disease progression during
  therapy or within 6 months of chemotherapy completion.'
- 3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.
- Additional Inclusion Criteria for HCC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar
  and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive
  diagnosis of HCC as per the American Association for the Study of Liver Diseases
  (AASLD) criteria in subjects with a confirmed diagnosis of cirrhosis.
- 2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination
  or monotherapy) in the locally advanced/metastatic setting, with a maximum of 2
  prior lines. Subjects with actionable target tumor mutation should have been previously
  treated with targeted therapy.
- 3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C.
- 4. Liver function status should be Child-Pugh (CP) Class A.
- 5. Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study
  drug.
- '6. Participants with large esophageal varices at risk of bleeding must be treated
  with conventional medical intervention: beta blockers or endoscopic treatment.'
- Additional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants
- 1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric
  that has relapsed or progressed after 1 prior line of systemic therapy in the locally
  advanced/metastatic setting. Subjects with PD-(L)1+ or MSI-H/dMMR should receive
  ICI treatment if ICIs are standard of care in the country, unless the subject is
  ineligible for ICI treatment.
- 2. If the participant has known history of HER2 positivity (defined by IHC 3+ or
  IHC 2+ and in situ hybridization \[ISH\] positive, as classified by American Society
  of Clinical Oncology - College of American Pathologists \[ASCO CAP\]) or actionable
  target, the subject must have been previously treated with a targeted therapy.
- Additional Inclusion Criteria for UC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic UC of the
  bladder, renal pelvis, ureter, or urethra. Participants with histological variants
  are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors
  are not allowed even if mixed histology.
- 2. Relapse or progression after at least 1 prior line of ICI-containing systemic
  therapy, and 1 prior line of systemic chemotherapy, given in combination with other
  anticancer therapy or separately, with a maximum of 3 prior therapy lines.
- 1. At least 1 line of therapy should include enfortumab vedotin in countries where
  enfortumab vedotin is approved and available.
- 2. Perioperative systemic therapies will be counted as 1 line of therapy.
- 3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in
  the perioperative or metastatic setting will suffice.
- 4. Subjects with actionable target tumor mutation should have been previously treated
  with targeted therapy.
- 5. The same regimen administered twice in different disease settings will be counted
  as 1 line of prior therapy.
- Additional Inclusion Criteria for CC Participants
- "1. Histologically confirmed unresectable or metastatic CC that was previously treated\
  \ with \u22651 prior line of systemic therapy in the locally advanced or metastatic\
  \ setting. Subjects with actionable target tumor mutation should have been previously\
  \ treated with targeted therapy."
- 2. Participants should receive prior anti-programmed death 1/programmed death-ligand
  1 treatment and/or tisotumab vedotin if those are standard of care in the country,
  unless the subject is ineligible for these treatments.
- Additional Inclusion Criteria for OVC Participants
- 1. Histologically confirmed high-grade serous OVC, high-grade endometrioid OVC,
  primary peritoneal cancer, or fallopian tube cancer that was previously treated
  with at least 1 line of platinum-based therapy and bevacizumab unless the subject
  is ineligible for treatment with bevacizumab.
- 2. Participant is no longer considered eligible for platinum-based therapy per the
  investigator's opinion or has progressed less than 180 days after the last dose
  of platinum therapy.
- 3. Participant is not considered primary platinum refractory and has not progressed
  during platinum treatment or within 4 weeks after the completion of platinum treatment.
- 4. Subjects with actionable target tumor mutation should have been previously treated
  with targeted therapy.
- Additional Inclusion Criteria for BTC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic BTC (intra-
  or extrahepatic cholangiocarcinoma or gallbladder carcinoma).
- 2. Relapse or progression after at least 1 prior line of systemic therapy, or 2
  prior lines of systemic therapy if the participant has an actionable target and
  has received targeted therapy.
- 3. Histological subtypes other than ampullary cancer, small cell cancer, lymphoma,
  sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms
  (Please note that the histological subtypes listed here are not allowed.)
- Additional Inclusion Criteria for HER2-Low BC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic BC.
- 2. Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according
  to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing, regardless
  of hormonal status.
- 3. Progression on or after treatment with trastuzumab deruxtecan (T-DXd).
- 4. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic
  therapy. Subjects with metastatic hormone receptor (HR)+ BC who have received endocrine-based
  therapy and have received at least 2 and a maximum of 3 prior lines of additional
  systemic therapy in the metastatic setting. Subjects with actionable target tumor
  mutation should have been previously treated with targeted therapy.
- Additional Inclusion Criteria for HER2 IHC 0 BC Participants
- 1. Pathologically or cytologically documented unresectable or metastatic BC.
- 2. Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to
  ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing, regardless
  of hormonal status.
- 3. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic
  therapy. Participants with metastatic HR+ BC who have received endocrine-based therapy
  and have received at least 2 and a maximum of 3 prior lines of additional systemic
  therapy in the metastatic setting. Subjects with actionable target tumor mutation
  should have been previously treated with targeted therapy.
- Additional Inclusion Criteria for Cutaneous (Acral and Non-acral) Melanoma Subjects
- 1. Histologically or cytologically confirmed cutaneous (acral and non-acral) melanoma.
- "2. Disease progression while on or after having received treatment with \u2265\
  1 prior line of ICI based therapy. Prior anti-PD-(L)1 therapy in the adjuvant setting\
  \ may be counted as 1 line if there is recurrence within 12 weeks of the last dose.\
  \ If the subject had BRAF mutated melanoma or other actionable target tumor mutation,\
  \ they must have had disease progression on targeted therapy as well."
- 'Participants who meet any of the following criteria will be disqualified from entering
  the study:'
- 1. Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted
  agents, including I-DXd.
- 2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an
  exatecan derivative (eg, T-DXd) due to treatment-related toxicities.
- 3. Clinically active brain metastases, spinal cord compression, or leptomeningeal
  carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids
  or anticonvulsants to control associated symptoms.
- 4. Inadequate treatment washout period before enrollment as specified in the protocol.
short_title: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan
  (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Daiichi Sankyo
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: 'This study is designed to assess the efficacy and safety of ifinatamab deruxtecan
  (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous
  cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer
  (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal
  junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer
  (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth
  factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and
  cutaneous melanoma.'
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Cohort 1: Endometrial Cancer'
      arm_internal_id: 0
      arm_description: Participants with recurrent or metastatic endometrial cancer
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 2: Head and Neck Squamous Cell Carcinoma'
      arm_internal_id: 1
      arm_description: Participants with recurrent or metastatic head and neck squamous
        carcinoma who were previously treated with 1 or more systemic therapy who
        received an intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 3: Pancreatic Ductal Adenocarcinoma'
      arm_internal_id: 2
      arm_description: Participants with recurrent or metastatic pancreatic ductal
        adenocarcinoma who were previously treated with 1 or more systemic therapy
        who received an intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 4: Colorectal Cancer'
      arm_internal_id: 3
      arm_description: Participants with recurrent or metastatic colorectal cancer
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 5: Hepatocellular Carcinoma'
      arm_internal_id: 4
      arm_description: Participants with recurrent or metastatic hepatocellular carcinoma
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd at the determined dose.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 6: Adenocarcinoma of esophagus, gastroesophageal junction,
        and stomach'
      arm_internal_id: 5
      arm_description: Participants with recurrent or metastatic adenocarcinoma of
        esophagus, gastroesophageal junction, and stomach who were previously treated
        with 1 or more systemic therapy who received an intravenous infusion of I-DXd
        12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 7: Urothelial carcinoma'
      arm_internal_id: 6
      arm_description: Participants with recurrent or metastatic urothelial carcinoma
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 8: Ovarian cancer'
      arm_internal_id: 7
      arm_description: Participants with recurrent or metastatic non-squamous ovarian
        cancer who were previously treated with 1 or more systemic therapy who received
        an intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 9: Cervical cancer'
      arm_internal_id: 8
      arm_description: Participants with recurrent or metastatic cervical cancer who
        were previously treated with 1 or more systemic therapy who received an intravenous
        infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 10: Biliary tract cancer'
      arm_internal_id: 9
      arm_description: Participants with recurrent or metastatic biliary tract cancer
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 11: Human epidermal growth factor 2 (HER2)-low breast cancer'
      arm_internal_id: 10
      arm_description: Participants with recurrent or metastatic human epidermal growth
        factor 2 (HER2)-low breast cancer who were previously treated with 1 or more
        systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 12: HER2 immunohistochemistry (IHC) 0 breast cancer'
      arm_internal_id: 11
      arm_description: Participants with recurrent or metastatic HER2 immunohistochemistry
        (IHC) 0 breast cancer who were previously treated with 1 or more systemic
        therapy who received an intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 13: Cutaneous melanoma'
      arm_internal_id: 12
      arm_description: Participants with recurrent or metastatic cutaneous melanoma
        who were previously treated with 1 or more systemic therapy who received an
        intravenous infusion of I-DXd 12 mg/kg.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ifinatamab deruxtecan'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        her2_status: Negative
        disease_status:
        - Unresectable
        - Metastatic
        - Advanced
        - Recurrent
        oncotree_primary_diagnosis: _SOLID_
